Biomanufacturing Expertise at Bayer HealthCare Pharmaceuticals

Bayer has a growing biotechnology presence in the San Francisco Bay Area and extending up the west coast of the United States. Our Berkeley biomanufacturing center produces Kogenate^® FS*, a key treatment for people living with hemophilia A. In 2007, the company acquired biomanufacturing facilities in Emeryville, Calif., which manufacture Betaseron^®, a leading biological product for the treatment of Multiple Sclerosis. This strategic acquisition further strengthened Bayer's growing biotech presence in and commitment to the Bay Area, one of the world's most active biotech corridors.

In addition to the Bay Area sites, a biomanufacturing facility in the Seattle, Washington area produces Leukine^®, the company's white blood cell growth factor.

* BETASERON^® (Interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

Important Safety Information
The most commonly reported adverse reactions are lymphopenia, injection-site reaction, asthenia, flu-like symptom complex, headache and pain. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms. BETASERON should be used with caution in patients with depression. Injection-site necrosis has been reported in 4% of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female patients should be warned about the potential risk to pregnancy. Cases of anaphylaxis have been reported rarely. See "Warnings," "Precautions," and "Adverse Reactions" sections of full Prescribing Information.

* Kogenate^® FS Antihemophilic Factor (Recombinant), is a recombinant Factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate^® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate^® FS. For important safety and use information, please see the full prescribing information.

* Product information is intended for U.S. Audiences Only

* LEUKINE^® (sargramostim) is a recombinant granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) for use following induction chemotherapy in older adults with acute myelogenous leukemia (AML) to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death. LEUKINE is also used in multiple stem cell transplantation settings click here to read the full indications.

Important Information
In controlled clinical trials across all indications, no significant differences were observed between LEUKINE® (sargramostim) and placebo-treated patients in the type or frequency of adverse events with the exception of an increase in skin-associated events in the LEUKINE group in the pivotal AML trial. There were occasional reports of fluid retention, dyspnea, supraventricular tachycardia, and laboratory abnormalities (increases in creatinine, bilirubin, and liver enzymes). Other adverse events have been reported. Please see full prescribing information which contains a more complete listing of indications, contraindications, warnings, precautions, adverse reactions, and dosage and administration guidelines